Amity Insight reports
The Life Code 06 Feb 2019
The areas covered within our latest Amity Insight: The Life Code, are at the cutting edge of developments in medical science where many of the ethical dilemmas are still to emerge, and to be regulated by policy makers. Consequently, to some degree we too are very early in the process of forming opinions.
However, the application of DNA related knowledge is creating a range of investment opportunities throughout the value chain in diagnostics, genetic editing, research and treatment.
The cutting edge nature of The Life Code does not align perfectly with UN Sustainable Development Goal #3 – Good Health & Wellbeing – which is focussed on conventional approaches to tackling medical inequality via bold commitments. However, Health & Wellbeing in the widest sense is one of EdenTree’s key sustainable themes focussed on improving the efficacy of treatments, reducing drug waste and powering discovery of new drugs for unmet conditions. The Life Code represents an exciting new area of investment exploration and discovery.
Nevertheless, our fairly recent mastery over the building blocks of life pose many unsolved ethical dilemmas. How do we protect this important data? What are the implications of genetic editing that may cause us to contemplate what it really means to be human, and how far should the life code itself be manipulated for profit? We do not have all the answers to these dilemmas, but we do hope you enjoy the voyage of discovery.
READ THE FULL REPORT
As always, we hope you enjoy this Amity Insight, and we welcome your comments and feedback.